Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: September 18, 2008
Last updated: April 9, 2013
Last verified: April 2013
The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with paclitaxel and carboplatin in adults with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells. In clinical practice, the combination of paclitaxel and carboplatin is an accepted treatment regimen for various solid tumors, including ovarian cancer, endometrial cancer and non-small cell lung cancer (NSCLC).

Condition Intervention Phase
Non-Small Cell Lung Cancer
Endometrial Carcinoma
Ovarian Carcinoma
Drug: XL147 (SAR245408),
Drug: paclitaxel
Drug: carboplatin
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • To evaluate the safety, tolerability, and MTD of XL147 administered in combination with paclitaxel (at doses up to 175 mg/m2) and carboplatin in subjects with advanced solid tumors [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: Yes ]
  • To evaluate the safety, tolerability, and MTD of XL147 administered in combination with paclitaxel (at doses up to 225 mg/m2) and carboplatin in subjects with NSCLC [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To investigate the relationship between selected biomarkers and efficacy and safety outcomes [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: No ]
  • To assess plasma pharmacokinetics (PK) of XL147, paclitaxel, and carboplatin when used in combination [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: No ]
  • To evaluate preliminary antitumor activity of XL147 in combination with carboplatin and paclitaxel [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: September 2008
Study Completion Date: October 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: XL147 (SAR245408),
Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
Drug: paclitaxel
Intravenous injection dosed once every three weeks
Other Name: Taxol®
Drug: carboplatin
Intravenous injection dosed once every three weeks


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of:

    • Advanced solid tumor that is no longer responding to therapies OR
    • Advanced or recurrent endometrial carcinoma OR
    • Advanced or recurrent ovarian carcinoma OR
    • Unresectable (Stage IIIB or IV) NSCLC
  • ECOG Performance Status 0-1 (ECOG status of 2 may be considered following discussion and agreement with sponsor)
  • Adequate organ and bone marrow function as defined by hematological and serum chemistry limits
  • At least 18 years old
  • Both men and women must practice adequate contraception
  • Informed consent

Exclusion Criteria:

  • Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including prior therapy with PI3K, AKT, or mTOR inhibitors, cytotoxic chemotherapy, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents
  • Known allergy or hypersensitivity to any of the components of the treatment formulations
  • Taking oral corticosteroids chronically or > 1 mg/day warfarin
  • Not recovered from the toxic effects of prior therapy
  • History of diabetes mellitus.
  • Uncontrolled intercurrent illness
  • Pregnant or breastfeeding
  • Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.
  • HIV positive
  • Diagnosis of another malignancy may exclude subject from study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00756847

United States, Missouri
Investigational Site Number
St. Louis, Missouri, United States, 63110
United States, Oklahoma
Investigational Site Number
Oklahoma City, Oklahoma, United States, 73104
United States, Texas
Investigational Site Number
Houston, Texas, United States, 77030-4009
United States, Wisconsin
Investigational Site Number
Madison, Wisconsin, United States, 53792-6164
Sponsors and Collaborators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Responsible Party: Sanofi Identifier: NCT00756847     History of Changes
Other Study ID Numbers: TED11435  XL147-003 
Study First Received: September 18, 2008
Last Updated: April 9, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Sanofi:
Solid Tumors
Ovarian Cancer
Endometrial Cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Endometrial Neoplasms
Ovarian Neoplasms
Adnexal Diseases
Bronchial Neoplasms
Carcinoma, Bronchogenic
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Lung Diseases
Lung Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Urogenital Neoplasms
Uterine Diseases
Uterine Neoplasms
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic processed this record on May 03, 2016